Eli Lilly leaves the Russian market and transfers its local business to the distributor Swixx Biopharma. This was told to the Kommersant newspaper by two former employees of the Eli Lilly division in the Russian Federation.
According to them, the preparation for this process began at the end of February with the change of top management in the company's representative office. Then, according to the Unified State Register of Legal Entities, the CEO of Lilly Pharma LLC — the Russian structure of Eli Lilly — Irina Zaporozhets was replaced in this position by Ekaterina Ibragimova. Part of the staff of Lilly Pharma, together with the top manager, will move to a new structure that Swixx Biopharma intends to create for the distribution of Eli Lilly drugs in Russia.
Lilly is one of the leading research companies in the field of healthcare.
